Plant Advanced Technologies SA (ALPAT.PA)
EUR 11.7
(-2.5%)
EUR 11.7
(-2.5%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 4.35 Million EUR | 4.6% |
| 2022 | 4.16 Million EUR | -5.55% |
| 2021 | 4.4 Million EUR | -23.03% |
| 2020 | 5.72 Million EUR | 164.31% |
| 2019 | 2.16 Million EUR | 66835.88% |
| 2018 | 3238.21 EUR | 47.22% |
| 2017 | 2199.61 EUR | 13.6% |
| 2016 | 1936.28 EUR | 9.0% |
| 2015 | 1776.35 EUR | -13.3% |
| 2014 | 2048.84 EUR | -99.81% |
| 2013 | 1.06 Million EUR | 552.17% |
| 2012 | 162.8 Thousand EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 FY | 4.35 Million EUR | 4.6% |
| 2023 Q4 | 4.35 Million EUR | 0.0% |
| 2023 Q2 | 4.52 Million EUR | 0.0% |
| 2022 FY | 4.16 Million EUR | -5.55% |
| 2022 Q2 | 4.69 Million EUR | 0.0% |
| 2022 Q4 | 4.16 Million EUR | 0.0% |
| 2021 Q4 | 4.4 Million EUR | 0.0% |
| 2021 FY | 4.4 Million EUR | -23.03% |
| 2021 Q2 | 3.45 Million EUR | 0.0% |
| 2020 Q2 | 3.08 Million EUR | 0.0% |
| 2020 FY | 5.72 Million EUR | 164.31% |
| 2020 Q4 | 2.51 Million EUR | 0.0% |
| 2019 Q2 | 2.11 Million EUR | 0.0% |
| 2019 FY | 2.16 Million EUR | 66835.88% |
| 2019 Q4 | 2.16 Million EUR | 0.0% |
| 2018 Q2 | 2864.17 EUR | 0.0% |
| 2018 FY | 3238.21 EUR | 47.22% |
| 2018 Q4 | 2491.66 EUR | 0.0% |
| 2017 Q2 | 1912.62 EUR | 0.0% |
| 2017 FY | 2199.61 EUR | 13.6% |
| 2017 Q4 | 1716.34 EUR | 0.0% |
| 2016 Q2 | 1648.09 EUR | 0.0% |
| 2016 FY | 1936.28 EUR | 9.0% |
| 2016 Q4 | 1936.28 EUR | 0.0% |
| 2015 FY | 1776.35 EUR | -13.3% |
| 2015 Q4 | 1776.35 EUR | 0.0% |
| 2015 Q2 | 1449.57 EUR | 0.0% |
| 2014 Q4 | 2048.84 EUR | 0.0% |
| 2014 Q2 | 1105.71 EUR | 0.0% |
| 2014 FY | 2048.84 EUR | -99.81% |
| 2013 FY | 1.06 Million EUR | 552.17% |
| 2013 Q4 | 1.06 Million EUR | 0.0% |
| 2012 FY | 162.8 Thousand EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -295.687% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 90.253% |
| Adocia SA | 4.54 Million EUR | 4.042% |
| Aelis Farma SA | 2.04 Million EUR | -112.72% |
| Biophytis S.A. | 3.11 Million EUR | -40.036% |
| Advicenne S.A. | 15.89 Million EUR | 72.594% |
| genOway Société anonyme | 5.51 Million EUR | 21.068% |
| IntegraGen SA | 642.28 Thousand EUR | -578.288% |
| Medesis Pharma S.A. | 1.2 Million EUR | -263.042% |
| Neovacs S.A. | 650 Thousand EUR | -570.232% |
| NFL Biosciences SA | 39.2 Thousand EUR | -11012.693% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | -122.234% |
| Sensorion SA | 1.24 Million EUR | -251.073% |
| Theranexus Société Anonyme | 2.46 Million EUR | -77.042% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | -11.763% |
| TheraVet SA | 1 Million EUR | -335.39% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | 36.917% |
| argenx SE | 15.35 Million EUR | 71.626% |
| BioSenic S.A. | 15.57 Million EUR | 72.025% |
| Celyad Oncology SA | 902 Thousand EUR | -382.983% |
| DBV Technologies S.A. | 4.52 Million USD | 3.745% |
| Galapagos NV | 4.94 Million EUR | 11.883% |
| Genfit S.A. | 62.25 Million EUR | 93.002% |
| GeNeuro SA | 6.49 Million EUR | 32.897% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -1166.427% |
| Innate Pharma S.A. | 30.6 Million EUR | 85.766% |
| Inventiva S.A. | 25.61 Million EUR | 82.993% |
| MaaT Pharma SA | 5.42 Million EUR | 19.696% |
| MedinCell S.A. | 52.8 Million EUR | 91.749% |
| Nanobiotix S.A. | 41.66 Million EUR | 89.543% |
| Onward Medical N.V. | 16.3 Million EUR | 73.283% |
| Oryzon Genomics S.A. | 3.45 Million EUR | -26.253% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | 87.731% |
| Oxurion NV | 117 Thousand EUR | -3623.512% |
| Pharming Group N.V. | 123.65 Million EUR | 96.477% |
| Poxel S.A. | 40.14 Million EUR | 89.148% |
| GenSight Biologics S.A. | 1.04 Million EUR | -315.697% |
| Transgene SA | 17 Thousand EUR | -25526.524% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 99.849% |
| Valneva SE | 132.76 Million EUR | 96.719% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |